Immunotherapy combo shows promise for rare nerve cancer in NF1 patients
NCT ID NCT04465643
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This early-phase study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) before standard treatments like surgery or radiation is safe and feasible for people with Neurofibromatosis Type 1 (NF1) who have a rare nerve tumor called MPNST. The trial enrolled 13 participants and focused on side effects and finding the best dose. The goal was to see if this approach could help control the disease before standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NERVE SHEATH TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Medical Institution
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.